Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.76 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.76 |
| ▸ | CSK | P41240 | 1/20 | 0.76 |
| ▸ | CAMK1G | Q96NX5 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 3/20 | 0.65 |
| ▸ | CCR4 | P51679 | 2/20 | 0.65 |
| ▸ | MELK | Q14680 | 5/20 | 0.61 |
| ▸ | LYN | P07948 | 1/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
| ▸ | FER | P16591 | 1/20 | 0.61 |
| ▸ | MATK | P42679 | 1/20 | 0.61 |
| ▸ | BLK | P51451 | 1/20 | 0.61 |
| ▸ | BMX | P51813 | 1/20 | 0.61 |
| ▸ | TEK | Q02763 | 1/20 | 0.61 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.61 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.61 |
| ▸ | CAMK1 | Q14012 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612950 | 1.00 | BTK (0.76) | BTKERBB4CSKCAMK1GFLT3 | |
| Pyrophosphoric Acid SCHEMBL1611259 | 0.92 | BTK (0.68) | BTKERBB4CSKCAMK1GFLT3 | |
| SCHEMBL3542142 | 0.87 | CCR4 (0.72) | BTKERBB4CSKCAMK1GFLT3 | |
| SCHEMBL3542141 | 0.87 | CCR4 (0.72) | BTKERBB4CSKCAMK1GFLT3 | |
| SCHEMBL3541029 | 0.86 | CCR4 (0.71) | BTKERBB4CSKCAMK1GFLT3 | |
| SCHEMBL3541032 | 0.86 | CCR4 (0.71) | BTKERBB4CSKCAMK1GFLT3 | |
| SCHEMBL7619465 | 0.86 | BTK (0.71) | BTKERBB4CSKCAMK1GFLT3 | |
| SCHEMBL7619472 | 0.86 | BTK (0.71) | BTKERBB4CSKCAMK1GFLT3 | |
| SCHEMBL3536852 | 0.85 | FLT3 (0.71) | BTKERBB4CSKCAMK1GFLT3 | |
| SCHEMBL3536853 | 0.85 | FLT3 (0.71) | BTKERBB4CSKCAMK1GFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240177-B1 | TREATMENTS FOR NEUROPATHY WITH XIB4035 | CHILDREN'S MEDICAL CENTER CORP (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | CHILDRENS MEDICAL CENTER (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-18 | — | — | US | disclosed |
| WO-2014160811-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20110086878-A1 | Treatments for Neuropathy | NIH-DEITR | 2011-04-14 | — | — | US | disclosed |
| US-7863295-B2 | Treatments for neuropathy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2240177-A2 | TREATMENTS FOR NEUROPATHY | Children's Medical Center Corporation (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009102570-A2 | TREATMENTS FOR NEUROPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NIH-DEITR | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | BTK 4200/4885ERBB4 1119/4885CSK 3142/4885 |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | BTK 4200/4885ERBB4 1119/4885CSK 3142/4885 |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | PMP22, GAP43, NGF | BTK 3547/4885ERBB4 1537/4885CSK 4098/4885 |
| US-20110086878-A1 | Treatments for Neuropathy | NGF, BDNF, NTRK2 | BTK 4200/4885ERBB4 1119/4885CSK 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.